New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTTSRO, MYGNMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
December 9, 2014
07:44 EDTTSROAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use